{"id":9272,"date":"2020-08-26T11:05:08","date_gmt":"2020-08-26T09:05:08","guid":{"rendered":"https:\/\/ggba.swiss\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/"},"modified":"2023-07-04T13:43:26","modified_gmt":"2023-07-04T11:43:26","slug":"lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/","title":{"rendered":"L&rsquo;EPFL d\u00e9veloppe le premier inhibiteur de synth\u00e8se pour des poumons artificiels"},"content":{"rendered":"<h4>Dans une \u00e9tude dirig\u00e9e par l\u2019EPFL, des scientifiques ont d\u00e9velopp\u00e9 un anticoagulant de synth\u00e8se qui, contrairement aux autres, ne provoque pas d\u2019effets secondaires h\u00e9morragiques. Cette mol\u00e9cule hautement efficace, s\u00e9lective et stable est capable de supprimer les thromboses tout en laissant le sang se coaguler normalement \u00e0 la suite d\u2019une blessure.<\/h4>\n<p>Les patients qui souffrent de thrombose, d\u2019embolie pulmonaire ou d&rsquo;accident vasculaire c\u00e9r\u00e9bral sont g\u00e9n\u00e9ralement trait\u00e9s avec des m\u00e9dicaments qui aident le sang \u00e0 circuler de fa\u00e7on plus r\u00e9guli\u00e8re \u00e0 travers leur corps. Les anticoagulants peuvent emp\u00eacher la formation ou la croissance de caillots sanguins. Ils contribuent ainsi au r\u00e9tablissement du patient apr\u00e8s des probl\u00e8mes cardiaques ou \u00e0 pr\u00e9venir de nouvelles complications.<\/p>\n<p>Cependant, ils fonctionnent en bloquant des enzymes qui contribuent \u00e0 arr\u00eater un saignement apr\u00e8s une blessure. De ce fait, potentiellement chaque anticoagulant disponible aujourd\u2019hui peut entra\u00eener une grave h\u00e9morragie, voire une h\u00e9morragie engageant le pronostic vital \u00e0 la suite d\u2019une blessure.<\/p>\n<p>Une enzyme appel\u00e9e \u00ab\u00a0facteur XII de la coagulation\u00a0\u00bb (FXII) a \u00e9t\u00e9 d\u00e9couverte il y a quelques ann\u00e9es, suite \u00e0 une \u00e9tude montrant que les souris d\u00e9pourvues de cette enzyme avaient un risque tr\u00e8s r\u00e9duit de thrombose sans avoir d&rsquo;effets secondaires h\u00e9morragiques.<\/p>\n<p>Aujourd&rsquo;hui, le <a href=\"https:\/\/www.epfl.ch\/labs\/lppt\/\" target=\"_blank\" rel=\"noopener\">Laboratoire des Prot\u00e9ines et Peptides Th\u00e9rapeutiques<\/a> du professeur Christian Heinis \u00e0 l&rsquo;<a href=\"https:\/\/www.epfl.ch\/fr\/\" target=\"_blank\" rel=\"noopener\">EPFL<\/a> a d\u00e9velopp\u00e9 le premier inhibiteur synth\u00e9tique du FXII. Cet inhibiteur est tr\u00e8s puissant, tr\u00e8s s\u00e9lectif et tr\u00e8s stable, avec une demi-vie plasmatique de plus de 120 heures.<\/p>\n<p>Avec un puissant inhibiteur du FXII en main, le laboratoire de Heinis voulait l&rsquo;\u00e9valuer dans des conditions r\u00e9elles de maladies. Pour ce faire, ils ont fait \u00e9quipe avec des experts en sang et en mod\u00e9lisation de maladies de l&rsquo;H\u00f4pital Universitaire de Berne (<a href=\"https:\/\/www.insel.ch\/fr\/\" target=\"_blank\" rel=\"noopener\">Inselspital<\/a>) et de l&rsquo;<a href=\"https:\/\/www.unibe.ch\/accs_direct\/informations_en_francais\/index_fra.html\" target=\"_blank\" rel=\"noopener\">Universit\u00e9 de Berne<\/a>. Cette collaboration entre les institutions des cantons de Vaud et de Berne a montr\u00e9 que l&rsquo;inhibiteur bloque efficacement la coagulation dans un mod\u00e8le de thrombose sans augmenter le risque de saignement.<\/p>\n<p>\u00ab\u00a0Ce nouvel inhibiteur de FXII est prometteur pour une thromboprotection s\u00fbre dans les poumons artificiels, utilis\u00e9s pour pallier une insuffisance pulmonaire avant une transplantation pulmonaire\u00a0\u00bb, conclut Heinis.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dans une \u00e9tude dirig\u00e9e par l\u2019EPFL, des scientifiques ont d\u00e9velopp\u00e9 un anticoagulant de synth\u00e8se qui, contrairement aux autres, ne provoque pas d\u2019effets secondaires h\u00e9morragiques. Cette mol\u00e9cule hautement efficace, s\u00e9lective et stable est capable de supprimer les thromboses tout en laissant le sang se coaguler normalement \u00e0 la suite d\u2019une blessure. Les patients qui souffrent de [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":9273,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1072],"class_list":["post-9272","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-rd-fr"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>L&#039;EPFL d\u00e9veloppe le premier inhibiteur de synth\u00e8se pour des poumons artificiels - Greater Geneva Bern area<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L&#039;EPFL d\u00e9veloppe le premier inhibiteur de synth\u00e8se pour des poumons artificiels - Greater Geneva Bern area\" \/>\n<meta property=\"og:description\" content=\"Dans une \u00e9tude dirig\u00e9e par l\u2019EPFL, des scientifiques ont d\u00e9velopp\u00e9 un anticoagulant de synth\u00e8se qui, contrairement aux autres, ne provoque pas d\u2019effets secondaires h\u00e9morragiques. Cette mol\u00e9cule hautement efficace, s\u00e9lective et stable est capable de supprimer les thromboses tout en laissant le sang se coaguler normalement \u00e0 la suite d\u2019une blessure. Les patients qui souffrent de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-26T09:05:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-04T11:43:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/Blood-Thinner-Enzyme-1-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"945\" \/>\n\t<meta property=\"og:image:height\" content=\"430\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"mathieu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"mathieu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/\"},\"author\":{\"name\":\"mathieu\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"headline\":\"L&rsquo;EPFL d\u00e9veloppe le premier inhibiteur de synth\u00e8se pour des poumons artificiels\",\"datePublished\":\"2020-08-26T09:05:08+00:00\",\"dateModified\":\"2023-07-04T11:43:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/\"},\"wordCount\":405,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Blood-Thinner-Enzyme-1-2.jpg\",\"keywords\":[\"R&amp;D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/\",\"name\":\"L'EPFL d\u00e9veloppe le premier inhibiteur de synth\u00e8se pour des poumons artificiels - Greater Geneva Bern area\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Blood-Thinner-Enzyme-1-2.jpg\",\"datePublished\":\"2020-08-26T09:05:08+00:00\",\"dateModified\":\"2023-07-04T11:43:26+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Blood-Thinner-Enzyme-1-2.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Blood-Thinner-Enzyme-1-2.jpg\",\"width\":945,\"height\":430},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L&rsquo;EPFL d\u00e9veloppe le premier inhibiteur de synth\u00e8se pour des poumons artificiels\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\",\"name\":\"mathieu\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/mathieu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L'EPFL d\u00e9veloppe le premier inhibiteur de synth\u00e8se pour des poumons artificiels - Greater Geneva Bern area","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/","og_locale":"fr_FR","og_type":"article","og_title":"L'EPFL d\u00e9veloppe le premier inhibiteur de synth\u00e8se pour des poumons artificiels - Greater Geneva Bern area","og_description":"Dans une \u00e9tude dirig\u00e9e par l\u2019EPFL, des scientifiques ont d\u00e9velopp\u00e9 un anticoagulant de synth\u00e8se qui, contrairement aux autres, ne provoque pas d\u2019effets secondaires h\u00e9morragiques. Cette mol\u00e9cule hautement efficace, s\u00e9lective et stable est capable de supprimer les thromboses tout en laissant le sang se coaguler normalement \u00e0 la suite d\u2019une blessure. Les patients qui souffrent de [&hellip;]","og_url":"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2020-08-26T09:05:08+00:00","article_modified_time":"2023-07-04T11:43:26+00:00","og_image":[{"width":945,"height":430,"url":"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/Blood-Thinner-Enzyme-1-2.jpg","type":"image\/jpeg"}],"author":"mathieu","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"mathieu","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/"},"author":{"name":"mathieu","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"headline":"L&rsquo;EPFL d\u00e9veloppe le premier inhibiteur de synth\u00e8se pour des poumons artificiels","datePublished":"2020-08-26T09:05:08+00:00","dateModified":"2023-07-04T11:43:26+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/"},"wordCount":405,"image":{"@id":"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Blood-Thinner-Enzyme-1-2.jpg","keywords":["R&amp;D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/","url":"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/","name":"L'EPFL d\u00e9veloppe le premier inhibiteur de synth\u00e8se pour des poumons artificiels - Greater Geneva Bern area","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Blood-Thinner-Enzyme-1-2.jpg","datePublished":"2020-08-26T09:05:08+00:00","dateModified":"2023-07-04T11:43:26+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Blood-Thinner-Enzyme-1-2.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Blood-Thinner-Enzyme-1-2.jpg","width":945,"height":430},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/lepfl-developpe-le-premier-inhibiteur-de-synthese-pour-des-poumons-artificiels\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"L&rsquo;EPFL d\u00e9veloppe le premier inhibiteur de synth\u00e8se pour des poumons artificiels"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab","name":"mathieu","url":"https:\/\/ggba.swiss\/fr\/author\/mathieu\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/9272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=9272"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/9272\/revisions"}],"predecessor-version":[{"id":17809,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/9272\/revisions\/17809"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/9273"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=9272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=9272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=9272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}